Postoperative Pain Clinical Trial
Official title:
Analgesic Efficacy of Preoperative Oral Administration of Dexketoprofen Trometamol in Third Molar Surgery, Compared to Postoperative Administration
The purpose of the present investigation is to evaluate the effectiveness of the preoperative administration of Dexketoprofen Trometamol, employing the third molar surgery model, when compared to postoperative administration of the same drug. It was hypothesized that preoperative oral Dexketoprofen trometamol will reduce the intensity of pain by 30% after 8 hours of the surgery, when compared with post-operative administration.
MODEL OF SURGICAL REMOVAL OF TOOTH IMPACTION. The model of Dental Impaction Pain Model
(DIPM) is the most utilized of all the acute pain models. Its popularity is due to a
well-established, well-validated, and extensively used postsurgery pain model in assessing
the efficacy of analgesics on inflammatory pain.
The surgical procedure is very standardized and surgery require either minimal or nothing
use of CNS depressant anesthetics. The methodology is similar to other models of acute pain;
however, the DIPM is much more versatile than most other models. The model can be easily
adapted to carry out studies of multiple-dose, pharmacokinetics / pharmacodynamics,
preventive interventions and analgesic efficacy
The impacted lower third molar extraction involves the manipulation of hard and soft tissue,
making the patient undergoes a series of effects which include acute pain, inflammation and
trismus in the immediate postoperative period and goes from 24 to 72 postoperative hours.
The pain associated with the surgical removal of a third molar is moderate to severe,
increasing with greater intensity during the first 24 hours after surgery with spikes of
pain between the first six to eight hours when using a conventional local anesthetic.
In this context, the control of pain and inflammation post-surgical associated with third
molar removal has been very varied; highlighting the use of anti-inflammatory pain relievers
non (NSAIDs) and some opioids.
PAIN. Pain is defined as the perception of a potentially injurious stimulus; which jointly
to several not pleasurable experiences (sensory, emotional and cognitive), same that are
caused by tissue damage (actual, potential or described in terms of such damage) and
manifested by certain reactions physiological, autonomic and behavioral. Pain is typically
classified as either acute or chronic.
Acute pain: is of sudden onset and is usually the result of a clearly defined cause such as
an injury. The acute pain includes the estimated time as necessary so that the tissues heal,
as described by John Bonica in 1953, usually in the span of a month, according to the
Committee of taxonomy of the pains of IASP, the length limit for a sharp pain is three
months, however should be noted that there are authors who continue classifying pain acute
with a duration of up to 6 months.
Chronic pain: is defined as pain that lasts more than 12 weeks, or the one that according to
the characteristics of their origin, exceeds time which could usually be defined a similar
pain. It is accompanied by psychological commitment to important behavior disorders that can
lead to depressive states; depending on the individual baseline emotional.
Although it can also be classified according to their structure (somatic or visceral) origin
and physiological mechanism (nociceptive or neuropathic).
The scheme to perceive pain needs: a) a peripheral structure that acts as a receiver; b) a
synapse in the spinal cord, c) pathways from spinal cord to superiority centers and d)
descending pathways from the superiority center to the marrow, which act as mainly
inhibitory mechanisms but also facilitated by change of neurotransmitters .
The study of the neurophysiology of pain has been an important advance in the knowledge of
the mechanism of the painful stimulus in the perioperative period describing a dynamic
system where multiple input have a place nociceptive, which conditions the first stage of
peripheral awareness that amplifies transmission of stimulation to condition a second tier
of central sensitization to keep in time.
MEASUREMENT OF PAIN. Clinicians and researchers have recognized that pain is a
multidimensional experience, which includes a number of qualities or measurable elements as
intensity, involvement, sensory quality, quality spatial (location), temporary quality, and
the impact on daily activities. While the focus on the measurement of pain remain in the
intensity, there has been an increase in the interest of measure other elements of pain.
PAIN INTENSITY SCALES. The domain of pain used in clinical studies and research is the
intensity of the pain. The three scales used to measure the intensity of pain are: a) visual
analog (VAS scale), b) the scale of numeric value (NRS) and c) the verbal value (VRS).
STRATEGIES IN THE MANAGEMENT OF DENTAL PAIN.
In dental practice pain of moderate to severe intensity conditions are usually treated with
Nonstereoidal anti-inflammatory (NSAIDs) drug, although there are other different types of
drugs used for this purpose that are described below:
- NASAIDs are a class of drugs that provides analgesic and antipyretic effects. Since
they have a mechanism of action in common based on the inhibition of cyclooxygenase
(COX) enzyme responsible for the biosynthesis of prostaglandins and general of
Eicosanoids. Unfortunately, prostaglandins mediate other physiological functions that
cause undesirables adverse effects.
- New inhibitors of COX show great power and analgesic effectiveness and are better at
reducing the incidence of adverse effects compared to the classic AINE´S.
DEXKETOPROFEN TROMETAMOL. Dexketoprofen is a new anti-inflammatory drug non-steroidal
(NSAID) belonging to the family of the arylpropionic acid derivatives. Dexketoprofen is the
enantiomer S (+) of the composite ketoprofen, a drug with analgesic effects and
anti-inflammatory clearly documented.
Dexketoprofen has been developed (dexketoprofen trometamol) tromethamine salt as a
formulation with a higher than the free acid aqueous solubility. Pharmacokinetic studies
performed in healthy individuals showed that oral administration of dexketoprofen trometamol
presented a kinetic favorable profile for use in acute pain compared to the formulation of
free acid or racemic ketoprofen.
Dexketoprofen trometamol, is one of the most powerful inhibitors of prostaglandin synthesis
"in vitro". 12.5-25 mg orally is given with a quickly absorbed on an empty stomach, which
has a strong binding to albumin and inactive metabolites after glucuronization renal
excretion. It is well accumulate in synovial fluid and its analgesic potency is comparable
to 50 mg of ketoprofen or diclofenac and more than 600 mg of ibuprofen, so its main
indication is acute postoperative pain.
The production of a unique isomer of ketoprofen formulation simplifies the pharmacokinetics
of the drug and allows a reduction of 50% in the dose. This can reduce adverse effects to
reduce the metabolic and renal work, rapid absorption appears to offer some protection
against gastrointestinal complications as a method to avoid gastrointestinal toxicity
different of the selectivity of COX presents a good profile of security and reported adverse
effects are similar to placebo in these studies, the uniqueness of the therapeutic profile
of the DKP.TRIS could be the result of a combination of factors which include the higher
power as it is given only the active molecule, inhibition of COX two isoenzymes, rapid
absorption from the gastrointestinal tract and high capacity to enter the CNS.
PREVENTIVE ANALGESIA. Preventive analgesia (PA) is an antinociceptive treatment which
prevents the establishment of the altered processing of the sensory input, that amplifies
and chronic postoperative pain. The PA concept was formulated by Crile at the beginning of
the century on the basis of clinical observations. There are two terms in English which
refer to the same concept: preemptive analgesia, which consists of a treatment that is given
before the surgical incision and maintained for intervention to avoid an altered sensory
processing that amplifies and chronic postoperative pain. Is usually to compare the same way
and the same drug management before and after the incision; and preventive analgesia
consists of a longer lasting analgesic effect which that would theoretically be expected
after administration of a certain drug on the basis of its pharmacological properties.
In oral surgery, primary hyperalgesia is the awareness of the receivers of the mucosa and
the periosteum by a range of mediators of inflammation such as prostaglandins. Secondary
hyperalgesia is central sensitization of neurons in the nucleus trigeminal and spinal supra
structures. Secondary hyperalgesia can be observed over the time, while the primary
hyperalgesia is provable within a few hours after the injury; Prostaglandins are synthesized
quickly after damage to the tissue and appear in significant concentrations 1 hour after
trauma.
The concept of preventive analgesia is based on the prior administration to the surgical
incision of a painkiller to dampen or prevent phenomena of hypersensitisation central in
order to reduce the consumption of analgesics in the postoperative period.
WORK PLAN. Using a format in which specify the inclusion and exclusion criteria, the
selection of the patients will be held, during this visit will also fill the form of
demographic data, status of the patient, current condition, medical history, physical
examination, x-ray and diagnostic studies. See annex 3.
Then patients will be randomized distributed in two groups of participants, group 1 and 2:
Experimental drugs. The randomized patient is determined to a group according with the
administration of the drug in two groups.
GROUP 1 Oral administration of dexketoprofen Trometamol 25 mg, 30 minutes before the
beginning of surgery and administered immediately at the end of the same placebo.
GROUP 2 The placebo is oral administered 30 minutes before the beginning of surgery and
administered immediately at the end of the same dexketoprofen Trometamol 25 mg.
Surgical procedure. All surgeries will be performed by the same surgeon, to achieve a local
anesthetic effect, a previous asepsis and antisepsis of the area will be necessary. The
lower alveolar nerve with reinforcement of the lingual nerve and long buccal nerve using 2
cartridges of lidocaine with epinephrine 2% with a concentration of 1:100 ml.
Once the anaesthetic effect is present, surgery can be performed, a flap of total thickness
of mucoperiosteal will be made, using a triangular incision design liberating the tissue at
the level of the second mandibular molar, subsequently the third molar extraction will be
performed. Finally the reposition of the flap and suturing will be made using black silk
suture (3-0).
In all cases the duration of the surgery procedure will be registered in every step. see
annex 4.
Measurement of the variables. Intensity of pain. For both groups, a measure will be
performed between the distance in mm from point 0 to the point that the patient indicates;
with the understanding that the point represents the intensity of the pain using the NRS,
values were registered in the NRS scale of each patient. This procedure will beginning after
the second intake of the drug or placebo (basal), after 8 hours (8-NRS), 24 hours, 48 hours
and 72 hours post operatory.
Time to remedication. The time in minutes that the patient request remedication with
dexketoprofen, registering again the intensity of pain will be registered.
Total of tablets consumed. The number of tablets consumed in the 72 hrs of the postoperative
will be recorded. The dosage of dexketoprofen 25mg will be standardized for every 8 hours,
and not to exceed 75mg every 24 hours until the patient deems necessary.
The antibiotic used in the clinical trial will be:
Clindamycin 300 mg every 8 hrs for 5 days. After 7 days of postoperative evolution, the
patient will return to the clinic for removal of stitches, evaluating the operative area and
general health condition, with this step, the attention will be concluded for the surgical
procedure and the medical discharge will be indicated.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT03181620 -
Sedation Administration Timing: Intermittent Dosing Reduces Time to Extubation
|
N/A | |
| Completed |
NCT04579354 -
Virtual Reality (VR) Tour to Reduce Preoperative Anxiety Before Anaesthesia
|
N/A | |
| Recruiting |
NCT06007378 -
Optimizing Postoperative Pain Control After Laparoscopic Colorectal Surgery
|
N/A | |
| Recruiting |
NCT05943015 -
Analgesic Efficacy of Quadratus Lumborum, Paravertebral Blocks
|
N/A | |
| Completed |
NCT04544228 -
Ketamine or Neostigmine for Serratus Anterior Plane Block in Modified Radical Mastectomy
|
N/A | |
| Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
| Completed |
NCT03286543 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System
|
N/A | |
| Completed |
NCT03663478 -
Continuous TQL Block for Elective Cesarean Section
|
Phase 4 | |
| Completed |
NCT04176822 -
Designing Animated Movie for Preoperative Period
|
N/A | |
| Completed |
NCT05170477 -
Influence of Apical Patency Concept Upon Postoperative Pain After Root Canal Treatment
|
N/A | |
| Not yet recruiting |
NCT04561856 -
Fascia Iliaca Block Supplemented With Perineural Vs Intravenous Dexamethasone
|
Phase 4 | |
| Completed |
NCT06425601 -
A Comparison of Silicone Versus Polyvinylchloride (PVC) Drains Following VATS Lobectomy
|
N/A | |
| Completed |
NCT03612947 -
TAP Block in Laparoscopic Cholecystectomy.
|
Phase 2 | |
| Completed |
NCT05974501 -
Pre vs Post Block in Total Knee Arthroplasty (TKA)
|
Phase 4 | |
| Completed |
NCT05995912 -
Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain
|
Phase 2 | |
| Completed |
NCT04571515 -
Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain
|
Phase 2 | |
| Active, not recruiting |
NCT04190355 -
The Effect of Irrigant Types Used During Endodontic Treatment on Postoperative Pain
|
N/A | |
| Recruiting |
NCT05145153 -
Incidence of Chronic Pain After Thoracic Surgery
|
||
| Recruiting |
NCT03697278 -
Monitoring Postoperative Patient-controlled Analgesia (PCA)
|
N/A |